Scientific Advisory Board

Our scientific advisors include world-renowned experts in oncology, genetics and drug development.

  • Lewis C. Cantley, Ph.D.

    Lewis C. Cantley, Ph.D., is Professor of Systems Biology, Chief, Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center.

  • Lynda Chin, M.D., Professor

    Lynda Chin, M.D., is a co-founder of AVEO. She is Chair of the Department of Genomic Medicine and the Scientific Director of the Institute for Applied Cancer Science at the University of Texas MD Anderson Cancer Center. She is also a senior associate member of the Broad Institute of MIT and Harvard.

  • Douglas Hanahan, Ph.D.

    Douglas Hanahan, Ph.D., currently holds joint appointments in Lausanne, Switzerland and San Francisco, California. He is an American Cancer Society research professor in the department of biochemistry and biophysics, and a member of the Comprehensive Cancer Center and the Diabetes Center at the University of California San Francisco. In addition, he is the director of the Swiss Institute for Experimental Cancer Research and a professor of Molecular Oncology at the Swiss Federal Institute of Technology Lausanne.

  • H. Robert Horvitz, Ph.D.

    H. Robert Horvitz, Ph.D., received the Nobel Prize in Physiology for Medicine in 2002. He is the David H. Koch professor of biology at the Massachusetts Institute of Technology; an investigator of the Howard Hughes Medical Institute; neurobiologist (neurology) at the Massachusetts General Hospital; and a member of the MIT McGovern Institute for Brain Research and the MIT Koch Institute for Integrative Cancer Research.

  • Tyler Jacks, Ph.D.

    Tyler Jacks, Ph.D. is director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. He is also a professor of biology at MIT and an investigator of the Howard Hughes Medical Institute.

  • Raju Kucherlapati, Ph.D.

    Raju Kucherlapati, Ph.D. has been a professor of Medicine at Harvard Medical School since 2001 and served as scientific director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics from 2001 to 2008. Dr. Kucherlapati was a founder of Cell Genesys, Inc., Abgenix, Inc. and Millennium Pharmaceuticals, Inc. and currently serves on the board of Enlight Biosciences LLC. Dr. Kucherlapati holds a B.S. in Biology from P.R. College, Kakinada, India, an M.S. in biology from Andhra University, Waltair, India and a Ph.D. from the University of Illinois at Urbana.

  • Charles L. Sawyers, M.D.

    Charles L. Sawyers, M.D., is an investigator of the Howard Hughes Medical Institute and the inaugural director of the HOPP at Memorial Sloan Kettering Cancer Center, where he is building a program of lab-based translational researchers across various clinical disciplines and institutional infrastructure to enhance the application of global genomics tools to clinical trials.